Cover Image

Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials

In two large clinical trials (ZOE-50 [NCT01165177] and ZOE-70 [NCT01165229]), two doses of the adjuvanted recombinant zoster vaccine (RZV) demonstrated >90% efficacy against herpes zoster in adults ≥50 years of age. Solicited adverse events (AEs) were collected for 7 days post-each dose in a stud...

Full description

Saved in:

Bibliographic Details
Main Authors:	Romulo Colindres (Author), Valentine Wascotte (Author), Alain Brecx (Author), Christopher Clarke (Author), Caroline Hervé (Author), Joon Hyung Kim (Author), Myron J. Levin (Author), Lidia Oostvogels (Author), Toufik Zahaf (Author), Anne Schuind (Author), Anthony L. Cunningham (Author)
Format:	Book
Published:	Taylor & Francis Group, 2020-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials
by: Lidia Oostvogels, et al.
Published: (2019)

Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention
by: Nicolas Lecrenier, et al.
Published: (2018)

Safety and reactogenicity of the adjuvanted recombinant zoster vaccine: experience from clinical trials and post-marketing surveillance
by: Joseph Fiore, et al.
Published: (2021)

Assessment of the potential public health impact of Herpes Zoster vaccination in Germany
by: Desmond Curran, et al.
Published: (2017)

Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial
by: Diana Alexandra Echeverria Proano, et al.
Published: (2024)

Immune responses to zoster vaccines
by: Myron J Levin, et al.
Published: (2019)

The adjuvanted recombinant zoster vaccine is efficacious and safe in Asian adults ≥ 50 years of age: a sub-cohort analysis of the ZOE-50 and ZOE-70 randomized trials
by: Joon Hyung Kim, et al.
Published: (2021)

Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults
by: Sue Ann Costa Clemens, et al.
Published: (2023)

Immune responses to the adjuvanted recombinant zoster vaccine in immunocompromised adults: a comprehensive overview
by: Alemnew F. Dagnew, et al.
Published: (2021)

Methods for predicting vaccine immunogenicity and reactogenicity
by: Patrícia Gonzalez-Dias, et al.
Published: (2020)

Radiobiological Basis of Low-Dose Irradiation in Prevention and Therapy of Cancer
by: Myron Pollycove
Published: (2007)

Studies with herpes zoster vaccines in immune compromised patients
by: Myron J. Levin, et al.
Published: (2017)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
by: Kriangkrai Tawinprai, et al.
Published: (2022)

Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019
by: Brandon J. Patterson, et al.
Published: (2021)

Low-dose Oral Thimerosal for the Treatment of Oral Herpes: Clinical Trial Results and Improved Outcome After Post-hoc Analysis
by: Stephen W. Mamber, et al.
Published: (2022)

Low-dose Oral Thimerosal for the Treatment of Oral Herpes: Clinical Trial Results and Improved Outcome After Post-hoc Analysis
by: Stephen W. Mamber, et al.
Published: (2022)

Long intervals between two doses of HPV vaccines and magnitude of the immune response: a post hoc analysis of two clinical trials
by: Vladimir Gilca, et al.
Published: (2019)

Immunogenicity and reactogenicity of heterologous COVID-19 vaccination in pregnant women
by: Chenchit Chayachinda, et al.
Published: (2023)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010)

EVALUATION OF REACTOGENICITY, SAFETY AND IMMUNOGENICITY OF INACTIVATED MONOVALENT VACCINE IN CHILDREN
by: A.N. Mironov, et al.
Published: (2010)

Herpes zoster dermatitis in a COVID-19 vaccinated healthy man after 1 dose of varicella vaccine
by: Farshid Etaee, MD, et al.
Published: (2022)

Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study
by: Anita E Heywood, et al.

Cannabinoids dosing for osteoarthritis
by: Sarah J. Miles, et al.
Published: (2024)

Responses to Low Doses of Ionizing Radiation in Biological Systems
by: Ludwig E. Feinendegen, et al.
Published: (2004)

The Clinical Efficacy of Gegen Qinlian Decoction in Treating Type 2 Diabetes is Positively Correlated with the Dose of Coptidis rhizoma: Three Randomized, Doubleblind, Dose-Parallel Controlled Clinical Trials
by: Kang X, et al.
Published: (2024)

Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study
by: Youssef Nader N, et al.
Published: (2010)

A randomized Phase I/II study to evaluate safety and reactogenicity of a heat-stable rotavirus vaccine in healthy adults followed by evaluation of the safety, reactogenicity, and immunogenicity in infants
by: Vibhu Kanchan, et al.
Published: (2020)

REACTOGENICITY OF ACELLULAR PERTUSSIS VACCINE AND THE POSSIBILITY OF ITS USE IN ELDER CHILDREN
by: M.G. Galitskaya, et al.
Published: (2008)

REACTOGENICITY OF ACELLULAR PERTUSSIS VACCINE AND THE POSSIBILITY OF ITS USE IN ELDER CHILDREN
by: M.G. Galitskaya, et al.
Published: (2008)

Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses
by: Giorgia Tiozzo, et al.
Published: (2023)

Dose-proportional pharmacokinetic properties of GLA5PR GLARS-NF1 controlled-release pregabalin in healthy Korean volunteers: a randomized, open, single-dose, parallel study
by: Shin KH, et al.
Published: (2018)

The rational dose for MaXingShiGan decoction is crucial for its clinical effectiveness in treating bronchial pneumonia: three randomized, double-blind, dose-parallel controlled clinical studies
by: Xuedong An, et al.
Published: (2023)

High dose of epinephrine does not improve survival of children with out-of-hospital cardiac arrest: Results from the French National Cardiac Arrest Registry
by: Morgan Recher, et al.
Published: (2022)

Immunogenicity, safety, and reactogenicity of combined reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine administered as a booster vaccine dose in healthy Russian participants: a phase III, open-label study
by: Asmik Asatryan, et al.
Published: (2021)

Comparison of pharmacopeial statistical methods applied in microbiological assay for antibiotics potency determination using parallel lines and three-dose level
by: Miriam de Fátima Vianna Leonel, et al.
Published: (2012)

Association between treatment response and dose of blonanserin transdermal patch in patients with acute schizophrenia: A post hoc cluster analysis based on baseline psychiatric symptoms
by: Yoshiteru Takekita, et al.
Published: (2024)

Low-Dose Cancer Risk Modeling Must Recognize Up-Regulation of Protection
by: Ludwig E. Feinendegen, et al.
Published: (2010)

Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
by: Nikolaos Giannelos, et al.
Published: (2023)

Recent Developments on Mobile Ad-Hoc Networks and Vehicular Ad-Hoc Networks
Published: (2021)

Ad Hoc Networks
Published: (2017)